Dr. Renu Dhasmana, Dr. Harsh Bahadur, Dr. Darshika Rawat


Purpose: To evaluate the effect of intravitreal triamcinolone in diabetic macular edema.
Methods: All diabetic patients presenting to ophthalmology OPD of a tertiary care hospital in Uttarakhand over a period
of one year, fullling the inclusion and exclusion criteria, were included in the study. Detailed eye examination, pre-injection FFA and OCT was
done. Single IVTA injection was given to proven cases of diabetic macular edema and patients were examined for improvement of vision and
change in macular thickness, at 6 and 12 weeks interval.
Results: Total 30 patients were included. There was increase in BCVA in the study group. There was signicant decrease in macular thickness in
all three groups at 6 weeks and 12 weeks (p=0.0015). Post injection the macular thickness reduced and BCVA improved, thus proving IVTA to be
effective in the treatment of DME.
Conclusion: the study showed that triamcinolone acetonide is an effective treatment of DME.


diabetic macular edema, IVTA

Full Text:



Arevalo, J. F. (2014). Diabetic macular edema: changing treatment paradigms. Current opinion in ophthalmology, 25(6), 502-507.

Raman R, Bhende M. Diabetic Macular Edema. Medical & Vision Research Foundations. 2015 Jun;33(2):50.

Browning, D. J., Stewart, M. W., & Lee, C. (2018). Diabetic macular edema: Evidence-based management. Indian journal of ophthalmology, 66(12), 1736.

Klein, R., Klein, B. E., Moss, S. E., & Cruickshanks, K. J. (1995). The Wisconsin epidemiologic study of diabetic retinopathy XV: the long-term incidence of macular edema. Ophthalmology, 102(1), 7-16.

Stewart, M. W. (2012). Corticosteroid use for diabetic macular edema: old fad or new trend?. Current diabetes reports, 12(4), 364-375.

Sonoda, Y., Arimura, N., Shimura, M., & Sakamoto, T. (2011). Early change of central macular thickness after intravitreous triamcinolone or bevacizumab in diabetic macular edema or retinal vein occlusion. Retina, 31(2), 290-297.

Tabakcı, B. N., & Ünlü, N. (2017). Corticosteroid treatment in diabetic macular edema. Turkish journal of ophthalmology, 47(3), 156.

Zhang, X., Zeng, H., Bao, S., Wang, N., & Gillies, M. C. (2014). Diabetic macular edema: new concepts in patho-physiology and treatment. Cell & bioscience, 4(1), 27.

Bhagat, N., Grigorian, R. A., Tutela, A., & Zarbin, M. A. (2009). Diabetic macular edema: pathogenesis and treatment. Survey of ophthalmology, 54(1), 1-32.

Bandello, F., Preziosa, C., Querques, G., & Lattanzio, R. (2014). Update of intravitreal steroids for the treatment of diabetic macular edema. Ophthalmic research, 52(2), 89-96.

Abraldes, M. J., Fernández, M., & Gómez-Ulla, F. (2009). Intravitreal triamcinolone in diabetic retinopathy. Current diabetes reviews, 5(1), 18-25.

Taylor, S. C., Montana, C., Shah, M., & SApte, R. (2018). Diabetic Macular Edema. Retina: Medical & Surgical Management, 309.

Jonas, J. B., & Degenring, R. (2002). Intravitreal injection of crystalline triamcinolone acetonide in the treatment of diffuse diabetic macular oedema. Klinische Monatsblatter fur Augenheilkunde, 219(6), 429-432.

Massin, P., Audren, F., Haouchine, B., Erginay, A., Bergmann, J. F., Benosman, R., ... & Gaudric, A. (2004). Intravitreal triamcinolone acetonide for diabetic diffuse macular edema: preliminary results of a prospective controlled trial. Ophthalmology, 111(2), 218-224.

Martidis, A., Duker, J. S., Greenberg, P. B., Rogers, A. H., Puliafito, C. A., Reichel, E., & Baumal, C. (2002). Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology, 109(5), 920-927.

Al Hinai, A., Wali, U. K., Rasool, T. A., & Rizvi, S. G. (2017). Experience of intravitreal triamcinolone acetonide for treatment of diabetic macular edema among Omani population. Oman journal of ophthalmology, 10(3), 177.

Ozkan, S., Fatih, H., Erkan, C., & Birol, T. (2019). Intravitreal bevacizumab versus bevacizumab and 1 mg triamcinolone acetonide in eyes with bilateral diabetic macular edema. International Eye Science, 19(1), 1-8.

Liu, Q., Hu, Y., Yu, H., Yuan, L., Hu, J., Atik, A., ... & Tang, S. (2015). Comparison of intravitreal triamcinolone acetonide versus intravitreal bevacizumab as the primary treatment of clinically significant macular edema. Retina, 35(2), 272-279.


  • There are currently no refbacks.